Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unsatisfied medical needs in the field of cardiovascular diseases, today announces the publication of its first shareholder newsletter.
Contents of this first issue:
- A word from Lionel Ségard, Chairman and Chief Executive Officer of Quantum Genomics : “2016 stands to be a year full of promise, with the international deployment of ambitious clinical trials.”
- Recent news : Quantum Genomics Symposium at the European Meeting on Hypertension and Cardiovascular Protection
- Zoom : Development in the United States
- Portrait : Docteur Keith C.Ferdinand
- Shareholder guide
The shareholder newsletter is available on the company's website at www.quantum-genomics.com, in the Shareholder letters section of the Investors tab.
Next meeting : General Shareholders' Meeting on 15 June 2016, at 10:00 am.
Chairman & Chief Executive Officer
+33 1 85 34 77 77
CFO – Investor Relations
+33 1 85 34 77 75
ACTUS finance & communication (Europe)
+33 1 53 67 36 73 / firstname.lastname@example.org
The Ruth Group (U.S.)
Lee Roth / Kirsten Thomas
Investor / Public Relations
+1 646-536-7012 / +1 508-280-6592
|ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially hypertension and heart failure.
The Company is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).
The Company has offices in Paris, France, and New York, NY, USA. For more information, please visit www.quantum-genomics.com.
Powered by Actusnews Wire (press release services) ©